Literature DB >> 30007463

Hymenoptera Anaphylaxis as a Clonal Mast Cell Disorder.

Patrizia Bonadonna1, Luigi Scaffidi2.   

Abstract

Up to 7% of adult patients with Hymenoptera venom allergy may suffer from a clonal mast cell disease. Patients with clonal mast cell disease and Hymenoptera venom anaphylaxis are commonly males, without skin lesions, and anaphylaxis is characterized by hypotension and syncope in the absence of urticaria and angioedema. A normal value of tryptase does not exclude a mastocytosis. The diagnosis of a mast cell disease leads to several therapeutic consequences concerning the treatment of Hymenoptera venom allergy as matter of fact these patients have to undergo long-life venom immunotherapy, to prevent further, potentially fatal severe reactions.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anaphylaxis; Clonal mast cell disease; Hymenoptera venom allergy; Monoclonal mast cell activation syndrome; Systemic mastocytosis; Tryptase

Mesh:

Substances:

Year:  2018        PMID: 30007463     DOI: 10.1016/j.iac.2018.04.010

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN: 0889-8561            Impact factor:   3.479


  8 in total

Review 1.  Recent advances in our understanding of mast cell activation - or should it be mast cell mediator disorders?

Authors:  Theoharis C Theoharides; Irene Tsilioni; Huali Ren
Journal:  Expert Rev Clin Immunol       Date:  2019-04-22       Impact factor: 4.473

2.  Venom immunotherapy in indolent systemic mastocytosis with high serum tryptase level.

Authors:  Ali Selcuk; Abdullah Baysan
Journal:  Hum Vaccin Immunother       Date:  2021-03-02       Impact factor: 3.452

3.  Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference.

Authors:  Jason Gotlib; Tracy I George; Melody C Carter; K Frank Austen; Bruce Bochner; Daniel F Dwyer; Jonathan J Lyons; Matthew J Hamilton; Joseph Butterfield; Patrizia Bonadonna; Catherine Weiler; Stephen J Galli; Lawrence B Schwartz; Hanneke Oude Elberink; Anne Maitland; Theoharis Theoharides; Celalettin Ustun; Hans-Peter Horny; Alberto Orfao; Michael Deininger; Deepti Radia; Mohamad Jawhar; Hanneke Kluin-Nelemans; Dean D Metcalfe; Michel Arock; Wolfgang R Sperr; Peter Valent; Mariana Castells; Cem Akin
Journal:  J Allergy Clin Immunol       Date:  2021-03-11       Impact factor: 14.290

4.  Development of a model care pathway for the management of Hymenoptera venom allergy: evidence-based key interventions and indicators.

Authors:  Maria Beatrice Bilò; Alice Corsi; Valerio Pravettoni; Donatella Bignardi; Patrizia Bonadonna; Oliviero Quercia; Marina Mauro; Elio Novembre; Rebecca Micheletti; Roberto Papa
Journal:  Clin Transl Allergy       Date:  2020-03-04       Impact factor: 5.871

5.  Editorial: Anaphylaxis - A Distinct Immunological Syndrome, but How Much Do We Really Understand?

Authors:  Mamidipudi Thirumala Krishna; Margitta Worm; Maria Beatrice Bilo
Journal:  Front Immunol       Date:  2019-12-19       Impact factor: 7.561

6.  Who Is Really at Risk for Anaphylaxis Due to COVID-19 Vaccine?

Authors:  Marco Caminati; Gabriella Guarnieri; Gianenrico Senna
Journal:  Vaccines (Basel)       Date:  2021-01-11

7.  Expression and existence forms of mast cell activating molecules and their antibodies in systemic lupus erythematosus.

Authors:  Yuping Wang; Tengkai Wang; Meijuan Cai; Shuzhen Zhu; Lijun Song; Qian Wang
Journal:  Immun Inflamm Dis       Date:  2021-11-16

Review 8.  Mastocytosis and Mast Cell Activation Disorders: Clearing the Air.

Authors:  Clayton Webster Jackson; Cristina Marie Pratt; Chase Preston Rupprecht; Debendra Pattanaik; Guha Krishnaswamy
Journal:  Int J Mol Sci       Date:  2021-10-19       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.